 |
enhancing the lives of those with sleep apnea
|
|
ARCHIVE
Postion Statements
Testimonies
- ASAA comments to CMS (PDF format)
- Public comments submitted by the ASAA at the MedCAC hearing in Baltimore Maryland, September 12, 2007 (RTF format)
- ASAA statement to the Joint Meeting of the FDA Dental Products and Ear, Nose, and Throat Device Panels, October 6, 2004.
- ASAA statement to the Medicare Coverage Advisory Committee, Centers for Medicare and Medicaid Services, September 28, 2004.
- ASAA statement presented to the Food and Drug Administration's Advisory Committee on Cephalon's application to have its drug modafinil indicated for the treatment of excessive sleepiness associated with disorders of sleep and wakefulness. September 25, 2003.
WAKE-UP CALL Newsletter
Past Issues:
2008
2007
2006
2005
2004
Other Publications
|
|